Cover Image

EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment

Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target for treatment with TKI is the epidermal growth factor receptor (EGFR), particularly in patients harboring activa...

Full description

Saved in:
Bibliographic Details
Main Authors: Brugger, Wolfram (Author) , Thomas, Michael (Author)
Format: Article (Journal)
Language:English
Published: 24 January 2012
In: Lung cancer
Year: 2012, Volume: 77, Issue: 1, Pages: 2-8
ISSN:1872-8332
DOI:10.1016/j.lungcan.2011.12.014
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.lungcan.2011.12.014
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500211006787
Get full text
Author Notes:Wolfram Brugger, Michael Thomas
Description
Summary:Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target for treatment with TKI is the epidermal growth factor receptor (EGFR), particularly in patients harboring activating mutations. However, despite initial responses and long lasting remissions, the development of secondary resistance inevitably leads to treatment failure. Analyzing recent data from various phase II/III trials it seems obvious that the single mode of action of gefitinib or erlotinib can provide temporary success only. Both preclinical and clinical evidence suggest that irreversible TKIs such as afatinib or PF00299804, or combined approaches using multiple kinase inhibition (e.g. EGFR and MET) and vertical inhibition by combination of small molecules and antibodies, seem to be more promising and will be the prevailing concepts to overcome secondary EGFR-TKI resistance for the near future.
Item Description:Gesehen am 13.09.2018
Physical Description:Online Resource
ISSN:1872-8332
DOI:10.1016/j.lungcan.2011.12.014

Similar Items